Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 30/05/2024 am IST			5-day change	1st Jan Change
2.75 ^USD	-0.00%		+1.48%	-17.91%

07/05	Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05/03	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Cyclerion Therapeutics, Inc. Announces Earnings Results for the Second Quarter of 2020

August 03, 2020 at 06:55 pm IST

Cyclerion Therapeutics, Inc. announced earnings results for the second quarter of 2020. Revenue, primarily from development services provided to Ironwood, was $0.7 million for the second quarter of 2020, as compared to $1.6 million for the second quarter of 2019. Net loss was approximately $20 million for the second quarter of 2020, as compared to $32 million for the second quarter of 2019.

Latest news about Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Cyclerion Therapeutics, Inc. Appoints Regina Graul as President	04/12	CI
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments	01/12	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director	24/11	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer	24/23/24	CI
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal	31/23/31	MT
Tisento Therapeutics, Inc. announced that it has received $81 million in funding from Cyclerion Therapeutics, Inc., Invus, Polaris, and other investors	31/23/31	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/23/29	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Cheryl Gault as Chief Operating Officer	28/23/28	CI
Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding	25/23/25	CI
Cyclerion Therapeutics to Implement 1-for-20 Reverse Stock Split	16/23/16	MT
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Cyclerion Therapeutics to Sell Zagociguat, CY3018 Assets to New Private Company	12/23/12	MT
J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.	11/23/11	CI
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment	03/23/03	MT
Cyclerion Therapeutics, Inc. announced that it expects to receive $5.000001 million in funding	31/23/31	CI
Cyclerion Therapeutics Says FDA Grants Orphan Drug Designation to Zagociguat; Shares Jump	27/23/27	MT
Cyclerion Gets FDA Orphan Designation for Zagociguat in Mitochondrial Diseases	27/23/27	DJ
Cyclerion Therapeutics' Zagociguat Gets FDA Orphan Drug Status	24/23/24	MT
Cyclerion Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22/23/22	CI
North American Morning Briefing : Futures Deep in -3-	15/23/15	DJ
A group including Cyclerion Therapeutics, Inc.'s Chief Executive Officer cancelled the acquisition of Certain Assets of Cyclerion Therapeutics, Inc..	22/22/22	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	04/22/04	CI

Chart Cyclerion Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Companyâs portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
CYCLERION THERAPEUTICS, INC.	-17.91%	6.98M
MODERNA, INC.	+48.67%	56.69B
IQVIA HOLDINGS INC.	-2.76%	41B
LONZA GROUP AG	+36.42%	38.11B
CELLTRION, INC.	-11.22%	26.89B
ICON PUBLIC LIMITED COMPANY	+9.25%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-23.10%	18.59B
BIO-TECHNE CORPORATION	+1.88%	12.39B
MEDPACE HOLDINGS, INC.	+26.43%	11.99B
UNITED THERAPEUTICS CORPORATION	+21.74%	11.88B

Other Biotechnology & Medical Research